TcrossGlobal

Empagliflozin improves HFpEF outcomes independent of blood pressure: The EMPEROR-Preserved Trial

In patients with heart failure with preserved LVEF (HFpEF), empagliflozin is effective and safe, independent of systolic blood pressure (SBP), according to the EMPEROR-Preserved trial reported by Dr. Michael Bohm and colleagues of Saarland University, Germany, in the February 1 issue of the European Heart Journal.

The EMPEROR-Preserved trial reported that empagliflozin reduced the risk of cardiovascular death/hea...

Continue reading this article

Select an option below:

Free Registration
Already have an account?
Log In

Introducing the main contents

Conference Reports

Timely delivery of scientific meetings from around the world, including AHA, ESC, TCT, EuroPCR, JCC, etc!

Complex PCI Cases

Features case reports on patients with complex lesions encountered in daily clinical practice.

Live Demonstration CoursesComing soon

In this section you will find live videos of catheter interventions for complex lesions.

What is TCROSS NEWS GLOBAL?

TCROSS NEWS Global, an affiliate of TCROSS Co., Ltd. Japan(established in 2005) is a cardiovascular news website which serves as a link between cardiologists, medical device manufacturers and industry stakeholders.
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.

Learn more about TCROSS NEWS Global

This website is automatically translated using Google Translate.